The article reports MEDS shares rose 124.1% to $3.63 in pre-market trading, but it gives no company news, so the report does not change how we read MEDS.
The article only lists pre-market price moves without any company news or operational detail. MEDS's price action draws attention but the piece gives no new facts about its business or results, and the company's market value is tiny, so the report does not change how we read MEDS today.
The rise could reflect traders reacting to rumor or momentum. That matters for intraday volatility and liquidity, but it does not provide a reliable signal about the company's prospects or products.